The Oncology InstituteTOI -3.12%56 9-Day RSI is 60.91 as of Jul. 01, 2026. GuruFocus rates TOI with a GF Score™ of 56/100 and a GF Value™ of $2.25 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 699 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 83.98% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for The Oncology Institute's 9-Day RSI or its related term are showing as below:
TOI's 9-Day RSI is ranked worse than 83.98% of 699
companies
in the Healthcare Providers & Services industry
Industry Median: 48.7
vs TOI: 60.91
The Oncology Institute (NAS:TOI) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Oncology Institute 9-Day RSI Related Terms
TOI vs CYH, SRTA, CCRN: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's 9-Day RSI falls into.
The Oncology Institute (NAS:TOI) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOI) has a 9-Day RSI of 60.91 as of Jul. 01, 2026. According to the industry distribution chart, The Oncology Institute ranks #587 out of 699 companies in the Healthcare Providers & Services industry, placing it in the top 84%.
Is The Oncology Institute's 9-Day RSI too high?
The Oncology Institute's current 9-Day RSI is 60.91. The Healthcare Providers & Services industry median 9-Day RSI is 48.70. The Oncology Institute's value of 60.91 is 25.1% above this industry median. Based on the distribution chart, The Oncology Institute ranks #587 out of 699 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's 9-Day RSI compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #587 out of 699 companies for 9-Day RSI. This places The Oncology Institute in the lower half of its industry. The industry median 9-Day RSI is 48.70. The Oncology Institute's value of 60.91 is 25.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 48.70, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Oncology Institute's current 9-Day RSI of 60.91 is 25.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 48.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current 9-Day RSI is 60.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.25, compared to a current price of $5.43 — trading 141.3% above its estimated fair value. The current 9-Day RSI is 60.91 and 25.1% above the Healthcare Providers & Services industry median of 48.70. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For The Oncology Institute (TOI), the current 9-Day RSI is 60.91 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Oncology Institute (TOI) Overvalued in 2026?
Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued.
The current stock price of $5.43 is trading 141.3% above its estimated GF Value™ of $2.25.
GuruFocus considers The Oncology Institute to be Significantly Overvalued.
Key valuation signals for TOI:
9-Day RSI: 60.91
GF Value™: $2.25 vs. price of $5.43 (141.3% above fair value)
Industry Position: 25.1% above the Healthcare Providers & Services median (#587 of 699)
No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOI
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOI has been successfully added to your 